TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Millennium Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 4.60nMAssay Description:Inhibition of C-Raf assessed as reduction in [33P]ATP incorporation into biotinylated substrate peptide after 3 hrs by flash plate assayMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf(Homo sapiens (Human))
Millennium Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 4.70nMAssay Description:Inhibition of wild-type B-RafMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase PLK3(Homo sapiens (Human))
Millennium Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals
Curated by ChEMBL
TargetSerine/threonine-protein kinase PLK3(Homo sapiens (Human))
Millennium Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals
Curated by ChEMBL
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Millennium Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Inhibition of C-Raf assessed as reduction in [33P]ATP incorporation into biotinylated substrate peptide after 3 hrs by flash plate assayMore data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Millennium Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Inhibition of C-Raf assessed as reduction in [33P]ATP incorporation into biotinylated substrate peptide after 3 hrs by flash plate assayMore data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Millennium Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals
Curated by ChEMBL
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Millennium Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 6.20nMAssay Description:Inhibition of C-Raf assessed as reduction in [33P]ATP incorporation into biotinylated substrate peptide after 3 hrs by flash plate assayMore data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Millennium Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals
Curated by ChEMBL
TargetSerine/threonine-protein kinase PLK3(Homo sapiens (Human))
Millennium Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals
Curated by ChEMBL
TargetDiscoidin domain-containing receptor 2(Homo sapiens (Human))
Millennium Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 7nMAssay Description:Inhibition of aurora kinase A autophosphorylation at T288 in human HCT116 cells by immunofluorescence analysisMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase PLK3(Homo sapiens (Human))
Millennium Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals
Curated by ChEMBL
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Millennium Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 9nMAssay Description:Inhibition of C-Raf assessed as reduction in [33P]ATP incorporation into biotinylated substrate peptide after 3 hrs by flash plate assayMore data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Millennium Pharmaceuticals
US Patent
Millennium Pharmaceuticals
US Patent
Affinity DataIC50: <10nMAssay Description:100 nL compounds in DMSO are added to wells of a 384 well microtitre plate (Greiner 780076). At room temperature: 5 ul VPS34 reaction buffer (Invitro...More data for this Ligand-Target Pair